Viking Therapeutics, Inc.
VKTX
$22.22
$0.703.25%
| Weiss Ratings | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.25 | |||
| Price History | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -13.47% | |||
| 30-Day Total Return | -23.03% | |||
| 60-Day Total Return | -36.26% | |||
| 90-Day Total Return | -58.03% | |||
| Year to Date Total Return | -45.96% | |||
| 1-Year Total Return | -68.65% | |||
| 2-Year Total Return | 25.61% | |||
| 3-Year Total Return | 710.95% | |||
| 5-Year Total Return | 293.97% | |||
| 52-Week High % Change | -73.71% | |||
| 52-Week Low % Change | 13.74% | |||
| Price | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $81.86 | |||
| 52-Week Low Price | $18.92 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | May 07, 2024 | |||
| Valuation | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.42B | |||
| Enterprise Value | 1.51B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.01 | |||
| Earnings Per Share Growth | 10.23% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 2.73 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $22.22 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -10.03 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 111.34M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 704 4660 | |||
| Address | 9920 Pacific Heights Boulevard San Diego, CA 92121 | |||
| Website | www.vikingtherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -14.78% | |||
| Return on Equity | -- | |||
| Income Statement | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -150.92M | |||
| Net Income (TTM) | -109.96M | |||
| Net Income Avl. to Common (TTM) | -109.96M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -43.94% | |||
| EPS Diluted (TTM) | -1.01 | |||
| EPS Diluted Growth (Q YOY) | -29.20% | |||
| Balance Sheet | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 902.61M | |||
| Cash Per Share (Q) | $8.11 | |||
| Total Current Assets (Q) | 907.22M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 880.28M | |||
| Current Ratio (Q) | 33.094 | |||
| Book Value Per Share (Q) | $7.89 | |||
| Total Assets (Q) | 908.32M | |||
| Total Current Liabilities (Q) | 27.41M | |||
| Total Debt (Q) | 1.12M | |||
| Total Liabilities (Q) | 28.04M | |||
| Total Common Equity (Q) | 880.28M | |||
| Cash Flow | VKTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -553.37M | |||
| Cash from Financing (TTM) | 612.46M | |||
| Net Change in Cash (TTM) | -28.84M | |||
| Levered Free Cash Flow (TTM) | -55.58M | |||
| Cash from Operations (TTM) | -87.79M | |||
